Wijnands JMA, et al. - Using population-based administrative data from British Columbia, Canada, authors analyzed the correlation between disease-modifying treatments (DMTs) for multiple sclerosis (MS) and infection-related medical encounters. Associations between DMT exposure (by DMT generation or class) and infection-related physician or hospital claims were scrutinized via recurrent time-to-events models. No link was disclosed between exposure to first-generation DMTs with an altered infection risk. Nonetheless, data exhibited a connection between exposure to the second-generation DMTs (natalizumab) with a 59% greater risk of an infection-related physician claim. Yielded results recommended continued pharmacovigilance.